Balyasny Asset Management LLC Viking Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $54.9 Billion
- Q2 2024
A detailed history of Balyasny Asset Management LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 57,400 shares of VKTX stock, worth $3.83 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
57,400
Previous 108,595
47.14%
Holding current value
$3.83 Million
Previous $8.9 Million
65.84%
% of portfolio
0.01%
Previous 0.02%
Shares
18 transactions
Others Institutions Holding VKTX
# of Institutions
442Shares Held
63.3MCall Options Held
6.23MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$674 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$402 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$342 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$150 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$124 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.12B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...